Background: International guidelines recommend adjuvant chemotherapy (ACT) for patients with stage III colon cancer. Whether efficacy observed in clinical trials translates to effectiveness in routine practice is less well understood. Here we describe use and outcomes of ACT in routine practice. Methods: All cases of colon cancer treated with surgery in Ontario 2002-2008 were identified using the populationbased Ontario Cancer Registry. Linked electronic records of treatment identified surgery and ACT use. Pathology reports were obtained for a random 25% sample of all cases; patients with stage III disease were included in the study population. Modified Poisson regression was used to evaluate factors associated with ACT. Cox proportional hazards model and propensity score analysis were used to explore the association between ACT and cancer-specific survival (CSS) and overall survival (OS). Results: The study population included 2,801 patients with stage III colon cancer; 66% (n=1,861) received ACT. ACT use rates varied substantially across age groups; 90% among patients aged 20 to 49 years versus 68% among those aged 70 to 79 years (P<.001). ACT use was inversely associated with comorbidity (P<.001) and socioeconomic status (P=.049). In adjusted analyses advanced age is associated with inferior CSS and OS. Use of ACT was associated with decreased risk of death from cancer (hazard ratio [HR], 0.63; 95% CI, 0.54-0.73) and decreased risk of death from any cause (HR, 0.63; 95% CI, 0.55-0.71). This result was consistent in the propensity score analysis. Conclusions: One-third of patients with stage III colon cancer in the general population do not receive ACT. Use of ACT in routine practice is associated with a substantial improvement in CSS and OS.
Background
International treatment guidelines have recommended 5-fluorouracil (FU)-based adjuvant chemotherapy (ACT) for patients with stage III colon cancer since the 1990s. 1 This is based on a series of randomized controlled trials (RCTs) showing a 30% reduction in death with a course of 5-FU, translating into an absolute improvement in 5-year overall survival (OS) of approximately 15%. 2 In 2004, a pivotal RCT demonstrated a further 4% improvement in 5 year OS with the addition of oxaliplatin to 5-FU (FOLFOX). 3 Another landmark RCT in 2005 showed that oral capecitabine chemotherapy could be substituted for 5-FU. 4 Accordingly, standard of care for patients with stage III colon cancer includes ACT with 5-FU/capecitabine with or without oxaliplatin. [5] [6] [7] It is well-known that results reported from clinical trials may not be realized in the general population. [8] [9] [10] This may relate to suboptimal adoption of new therapies in clinical practice. It may also relate to the fact that patients, providers, and health systems differ considerably between high-volume specialized centers and routine practice. 11 Accordingly, it may be misleading to assume that outcomes achieved in routine practice are comparable to those reported in the published literature. Population-based outcome studies are useful to describe practices and outcomes achieved in routine practice. 12, 13 Although a number of studies have previously reported rates of use of ACT for stage III colon cancer in routine clinical practice, [14] [15] [16] [17] [18] [19] [20] [21] limited literature has evaluated whether the efficacy of ACT observed in RCTs translates into effectiveness in the general population. To our knowledge, only 5 population-based reports have evaluated the effectiveness of ACT in stage III colon cancer. All of these reports are from the United States, 4 studies are restricted to elderly patients (>65 years of age), and 4 reports describe outcomes achieved in the 1990s. [14] [15] [16] 19, 22 We undertook a population-based study with the following objectives: to describe the use of ACT for stage III colon cancer in routine practice and to evaluate the effectiveness of ACT in the general population.
Methods

Study Design and Population
This is a population-based, retrospective cohort study to describe management and outcome of resected stage III colon cancer in the Canadian province of Ontario. Ontario has a population of approximately 13.5 million people and a single-payer universal health insurance program. 
Data Sources and Linkage
The OCR is a passive, population-based cancer registry that captures diagnostic and demographic information on at least 98% of all incident cases of cancer in the province of Ontario. 23 The OCR also provides information about vital status and cause of death. Records of hospitalization from the Canadian Institute for Health Information (CIHI) provided information about surgical procedures; these records are known to have a very high level of completeness for colorectal cancer surgery. 24 Provincial physician billing records from the Ontario Health Insurance Plan, treatment records from regional cancer centers, and provincial records of chemotherapy delivery were used to identify chemotherapy use. A team of trained data abstractors reviewed the pathology reports and entered information about disease extent into an electronic database.
Measures and Outcomes
Indicators of the socioeconomic status (SES) of the community in which patients resided at diagnosis were linked as described previously. 25 Quintiles (Q) of the median household income were based on the household income distribution for the full province of Ontario. Q1 represents the communities where the poorest 20% of the Ontario population resided. Geographic regions reflect the catchment areas for Ontario's regional cancer centers. 25 Comorbidity was classified using the Charlson Comorbidity Index modified for administrative data based on all noncancer diagnoses recorded during any hospital admission within 5 years before surgery. 26 A surgical hospital was identified for each case included in the study population. Each case was assigned a hospital volume index based on the total number of colon cancer resections performed (ie, all colon cancer resections identified and not just those eligible cases with stage III disease) in the 12 months before the surgical date. The hospitals were divided into quartiles of annual hospital volume. We used the same approach to derive a surgeon volume index for each patient.
ACT was defined as chemotherapy initiated within 16 weeks after surgery; neoadjuvant chemotherapy was defined as treatment given within 16 weeks before surgery.
OS and cancer-specific survival (CSS) were determined from date of primary tumour resection. To account for possible cause of death miscoding, CSS included death from any cancer. Complete informa-tion about vital status in the OCR was available up to December 31, 2012; cause of death was available up to December 31, 2010 . The primary outcome end point was CSS. CSS was prioritized over OS because it was believed likely to be less vulnerable to bias from unmeasured prognostic factors. Because the survival measure began before the chemotherapy exposure window ended (ie, at 16 weeks), our results were vulnerable to immortal person-time bias, whereby patients dying during the exposure window have a lower chance of receiving treatment; this would artificially worsen survival of the no-ACT group. 19 Accordingly, we excluded patients dying within 16 weeks of surgery from all survival analyses.
Statistical Analysis
Comparisons of proportions between study groups were made using the chi square test. Survival was determined from date of surgery using the KaplanMeier technique, and comparisons between groups were made using the log-rank test. Factors associated with treatment practices were evaluated by modified Poisson regression. The association between patient-, disease-, and treatment-related factors with OS/CSS was evaluated using the Cox proportional hazards regression model. To control for confounding variables when exploring the association between ACT and survival, we also used the propensity score technique in the Cox proportional hazards model. The propensity scores allowed us to create 5 propensity strata with balanced confounding variables between patients who did and did not receive ACT. Survival of patients treated with ACT was compared with those without ACT within each stratum using a Cox proportional hazards model; a summary hazard ratio (HR) combining the results across quintiles was calculated. 27 Results were considered statistically significant at a P value of less than .05. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Study Population
Linked administrative data sets identified 25,613 potentially eligible patients who underwent resection of primary colon cancer in 2002-2008 ( Figure 1 ). Surgical pathology reports were reviewed for 7,519 randomly selected cases. The age, sex, comorbidity, and survival of these randomly selected cases did not differ substantially from those of the 18,094 unselected cases (see supplemental eTable 1 and eFigure 1, available with this article at JNCCN.org). Among the 7,519 randomly selected cases, 270 (4%) were excluded ( Figure 1 ). Among 2,920 patients with stage III disease, 119 (4%) died within 30 days. Accordingly, the study population included 2,801 patients; survival analyses are restricted to the 2,650 patients alive 16 weeks after surgery. Characteristics of the study population are shown in Table 1 . The median age was 70 years and 52% were male.
Use of ACT
ACT was delivered to 66% (1,861/2,801) of the study population. Use rates remained stable throughout the study period (range, 64%-70%; P=.421). Specific regimens were identified for 69% (1,282/1,861) of ACT cases. Among these cases, 27% (343/1,282) received 5-FU alone, 19% (243/1,282) received capecitabine, 38% (487/1,282) received FOLFOX, and 16% (209/1,282) received FOLFIRI. Patients with advanced age, greater comorbidity, and/or lower SES were substantially less likely to receive ACT (Table 2 ). Increased postoperative length of stay was associated with lower use of ACT. There was no significant variation in use of ACT by geographic region, hospital volume, or surgeon volume. Random selection
Effectiveness of ACT
Five-year CSS and OS rates for all patients were 56% (95% CI, 54%-59%) and 51% (95% CI, 49%-53%), respectively. Among ACT-treated cases, unadjusted CSS and OS rates at 5 years were 62% (95% CI, 59%-64%) and 59% (95% CI, 56%-61%), respectively. In adjusted analyses, greater age is associated with inferior CSS and OS ( 
Discussion
This report describes the use and effectiveness of ACT for stage III colon cancer in the general population. Several important findings have emerged. First, one-third of patients with stage III colon cancer were not treated with ACT. Second, the most significant predictor of ACT use was patient age; treatment rates decreased markedly with advanced age. Third, long-term survival after ACT in the general population is substantially lower than outcomes reported in the relevant clinical trials. Finally, use of ACT in routine practice is associated with a substantial reduction in the risk of death. It is useful to consider our study results in light of the existing literature. Although a number of studies have described use rates of ACT for stage III colon cancer in routine practice, many of them are restricted to patients older than 65 years of age treated in the United States; ACT use rates in these US studies range from 42% through 75%. 14, 15, 19, 28, 29 In a recent study of patients aged 20 years or older randomly selected from the SEER database, Murphy et al 21 found that ACT treatment rates for stage III colon cancer peaked at 72% in 2005 and declined slightly to 66% in 2010. They found that advanced age and greater comorbidity was associated with lower rates of ACT. Two studies using the US National Cancer Data Base (NCDB) 16 ACT was delivered to 50% of patients. Age, comorbidity, and SES were associated with use of ACT. They also observed significant geographic variation in treatment rates. Two smaller Canadian studies have reported similar rates of ACT use (53% and 55%). 30, 31 Our observed ACT use rate of 66% in Ontario during 2002-2008 is greater than reported in earlier Canadian studies, yet remains substantially lower than found in other population-based reports from the United States and Sweden.
Our results also provide insight into whether the efficacy of ACT observed in RCTs translates into effectiveness in routine practice. Five-year OS of patients treated with ACT in the contemporary MOSAIC (The Maudsley Outpatient Study of Treatments for Anorexia Nervosa and Related Conditions) and X-ACT (Xeloda in Adjuvant Colon Cancer Therapy) RCTs was in the range of 68% to 76%. 32, 33 To our knowledge, only 2 populationbased studies report long-term survival of patients with stage III colon cancer treated with ACT, both of which use US SEER data and are restricted to patients aged 65 years or older. 14, 22 In both studies, the 5-year OS of patients treated with ACT was approximately 55%. In our study, the 5-year OS of all patients was 51%, and was 46% among patients aged 65 years or older. These data suggest that the survival of patients with stage III colon cancer treated with ACT in routine practice is considerably lower than that reported in RCTs. This highlights the fact that patients in clinical trials may be very different from patients seen in routine practice.
In the IMPACT (International Multicentre Pooled Analysis of Colon Cancer Trials) meta-analysis, 2 5-FU-based ACT was associated with a 30% reduction in the risk of death. The observed treatment effect of ACT in our study (HR for OS, 0.63; 95% CI, 0.55-0.71) is comparable to relevant RCTs and other population-based analyses. Four studies have used SEER data to evaluate the effectiveness of ACT compared with surgery in elderly patients with stage III colon cancer; ACT was associated with improved survival in each of these studies (HR for OS range, 0.51-0.73). 14, 15, 19, 22 In the most recent of these reports, Sanoff et al 19 used SEER data to evaluate ACT effectiveness in a cohort of patients older than 75 years 16 reported the only study that evaluated the effectiveness of ACT in a population of all ages. Using the NCDB, the authors identified 48,758 patients treated during 1998-2002. Cases with surgery and ACT were classified as being adherent to guidelines. In propensity score adjusted analyses, they found improved OS for cases with guideline-adherent care (HR, 0.53; 95% CI, 0.51-0.55).
Our study provides detailed data regarding the use of ACT and outcomes of patients with stage III colon cancer in a contemporary population-based cohort; however, several methodologic limitations merit comment. The study population was identified using linked administrative health databases. Although the OCR and the Canadian Institute for Health Information data sets are known to be consistent and complete, 23, 24, 34 it is possible that our results may be biased by misclassification. Although the electronic data sources used in this study describe general aspects of disease, treatment, and outcome for all patients in the province, detailed information related to stage carcinoembryonic antigen level, chemotherapy dose/cycles, treatment toxicity, and performance status is not available, and this limits our ability to evaluate the appropriateness of case selection for ACT.
It is possible that other unmeasured confounders may have contributed to the observed survival benefit with ACT. As with any retrospective cohort study, the finding that treatment is associated with improved outcome may reflect unmeasured differences (ie, comorbidity) between patients who were treated and those who were not. Confounding could have accounted for the observed association only if an unmeasured confounder was extremely unequally distributed between treated and untreated groups and was associated with a large increase in risk of death. Even in the setting of persistent residual confounding, the observed effect size is large enough that we believe the study results demonstrate the effectiveness of ACT in routine practice. We believe our results are made more convincing based on the fact that we observe a large treatment effect for CSS, which may be less prone to the effect of additional comorbidity than OS. Moreover, in a separate analysis of patients with stage II colon cancer, we did not observe any benefit to ACT (data not shown). If residual confounding explains the ACT treatment effect in stage III colon cancer, one might expect to see a similar phenomenon in patients with stage II disease. The results of our Cox model analysis were consistent using propensity score methodology, which may further reduce bias from unmeasured confounders. 35 Our study population was identified from the OCR and is therefore unselected, and, unlike most of the existing literature, includes patients of all ages. Because of the work required to manually review surgical pathology reports, our study population is a random sample of approximately 25% of all cases treated in Ontario during the study period. There were no substantial differences in demographic characteristics, ACT treatment rates, and survival outcomes between the randomly selected cases and the cases not included in our study population (supplemental eTable 1 and eFigure 1). We did not obtain pathology reports for cases that involved surgery in 2005. We believe it is very unlikely that this would bias our results in any significant way, because there were no observed temporal trends in practice or outcome between 2002 and 2008. During the study period, adjuvant oxaliplatin was not readily available in Ontario; for that reason, our results do not provide insight into the differential effect of oxaliplatincontaining ACT and therefore may be less generalizable to contemporary practice.
A total of 16% of patients in our study received FOLFIRI (irinotecan, 5-FU, leucovorin), which is not a standard adjuvant regimen. We believe that this reflects 2 groups of patients. First, most of these patients were treated with ACT in the early years before the negative trials of adjuvant FOLFIRI were reported, and therefore reflect true ACT (either onstudy or off-study). Second, it is possible that some of these cases were found to have metastatic disease within 16 weeks after surgery and were therefore started on palliative FOLFIRI chemotherapy.
Conclusions
In this contemporary population-based study of stage III colon cancer, one-third of patients did not receive ACT. We observed large differences in ACT use across age groups. Our data demonstrate that ACT for stage III colon cancer is associated with a substantial survival benefit in routine clinical practice. 
